PMC:7161517 / 21155-21361 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T124","span":{"begin":79,"end":83},"obj":"Body_part"},{"id":"T125","span":{"begin":174,"end":180},"obj":"Body_part"}],"attributes":[{"id":"A124","pred":"fma_id","subj":"T124","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A125","pred":"fma_id","subj":"T125","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"al trial (Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury; NCT01597635), patients with ARDS who were treated with rhACE2 exhibited decreased plasma Ang II and elevated plasm"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T64","span":{"begin":79,"end":83},"obj":"Body_part"}],"attributes":[{"id":"A64","pred":"uberon_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"al trial (Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury; NCT01597635), patients with ARDS who were treated with rhACE2 exhibited decreased plasma Ang II and elevated plasm"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T85","span":{"begin":73,"end":90},"obj":"Disease"},{"id":"T87","span":{"begin":84,"end":90},"obj":"Disease"},{"id":"T88","span":{"begin":120,"end":124},"obj":"Disease"}],"attributes":[{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A86","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0015796"},{"id":"A87","pred":"mondo_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A88","pred":"mondo_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"}],"text":"al trial (Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury; NCT01597635), patients with ARDS who were treated with rhACE2 exhibited decreased plasma Ang II and elevated plasm"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T211","span":{"begin":79,"end":83},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T212","span":{"begin":79,"end":83},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T213","span":{"begin":174,"end":180},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"al trial (Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury; NCT01597635), patients with ARDS who were treated with rhACE2 exhibited decreased plasma Ang II and elevated plasm"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T259","span":{"begin":32,"end":34},"obj":"Chemical"},{"id":"T260","span":{"begin":39,"end":41},"obj":"Chemical"},{"id":"T261","span":{"begin":185,"end":187},"obj":"Chemical"}],"attributes":[{"id":"A259","pred":"chebi_id","subj":"T259","obj":"http://purl.obolibrary.org/obo/CHEBI_74792"},{"id":"A260","pred":"chebi_id","subj":"T260","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"},{"id":"A261","pred":"chebi_id","subj":"T261","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"al trial (Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury; NCT01597635), patients with ARDS who were treated with rhACE2 exhibited decreased plasma Ang II and elevated plasm"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T29","span":{"begin":73,"end":90},"obj":"Phenotype"}],"attributes":[{"id":"A29","pred":"hp_id","subj":"T29","obj":"http://www.orpha.net/ORDO/Orphanet_178320"}],"text":"al trial (Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury; NCT01597635), patients with ARDS who were treated with rhACE2 exhibited decreased plasma Ang II and elevated plasm"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T750","span":{"begin":79,"end":83},"obj":"UBERON:0002048"},{"id":"T751","span":{"begin":174,"end":180},"obj":"UBERON:0001969"},{"id":"T752","span":{"begin":181,"end":187},"obj":"PR:000036009"},{"id":"T79951","span":{"begin":60,"end":64},"obj":"G_3;PG_10;PR:000003622"},{"id":"T75956","span":{"begin":118,"end":125},"obj":"UBERON:0000948"},{"id":"T51050","span":{"begin":174,"end":180},"obj":"UBERON:0001969"}],"text":"al trial (Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury; NCT01597635), patients with ARDS who were treated with rhACE2 exhibited decreased plasma Ang II and elevated plasm"}

{"project":"LitCovid-PubTator","denotations":[{"id":"922","span":{"begin":181,"end":187},"obj":"Gene"},{"id":"928","span":{"begin":59,"end":67},"obj":"Species"},{"id":"929","span":{"begin":106,"end":114},"obj":"Species"},{"id":"931","span":{"begin":45,"end":55},"obj":"Chemical"},{"id":"932","span":{"begin":147,"end":153},"obj":"Chemical"},{"id":"940","span":{"begin":39,"end":41},"obj":"Disease"},{"id":"941","span":{"begin":73,"end":90},"obj":"Disease"},{"id":"942","span":{"begin":120,"end":124},"obj":"Disease"}],"attributes":[{"id":"A922","pred":"tao:has_database_id","subj":"922","obj":"Gene:183"},{"id":"A928","pred":"tao:has_database_id","subj":"928","obj":"Tax:9606"},{"id":"A929","pred":"tao:has_database_id","subj":"929","obj":"Tax:9606"},{"id":"A940","pred":"tao:has_database_id","subj":"940","obj":"MESH:D010300"},{"id":"A941","pred":"tao:has_database_id","subj":"941","obj":"MESH:D055371"},{"id":"A942","pred":"tao:has_database_id","subj":"942","obj":"MESH:D012128"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"al trial (Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury; NCT01597635), patients with ARDS who were treated with rhACE2 exhibited decreased plasma Ang II and elevated plasm"}